Compare SCM & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | KROS |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 206.0M |
| IPO Year | 2012 | 2020 |
| Metric | SCM | KROS |
|---|---|---|
| Price | $7.27 | $10.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 250.7K | 217.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $0.33 | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $117.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.83 | $9.69 |
| 52 Week High | $14.85 | $22.55 |
| Indicator | SCM | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 39.11 |
| Support Level | $6.83 | $9.74 |
| Resistance Level | $9.27 | $11.55 |
| Average True Range (ATR) | 0.34 | 0.54 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 23.86 | 6.79 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.